BRIEF-GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
Reuters
Oct 23
BRIEF-GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
Oct 23 (Reuters) - GT Biopharma Inc GTBP.O:
GT BIOPHARMA PROVIDES ENROLLMENT UPDATE ON GTB-3650 PHASE 1 TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD33 EXPRESSING HEMATOLOGIC MALIGNANCIES
GT BIOPHARMA INC - ADVANCES TO COHORT 4 WITH 10 UG/KG/DAY DOSE
GT BIOPHARMA INC - SCREENING PATIENTS FOR COHORT 4, DOSING TO START SOON
GT BIOPHARMA INC - NEXT UPDATE EXPECTED IN Q1 2026 WITH DOSE ESCALATION
Source text: ID:nGNX1MpMR5
Further company coverage: GTBP.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.